ITGAX and systemic lupus erythematosus: Given the high expression of A2AR in T-bet CD11c B cells [96], the efficacy of A2AR agonist treatment has recently been demonstrated in lupus-prone mice [98], suggesting that A2AR may be a novel therapeutic target in RA.